Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   38520   clinical trials with a EudraCT protocol, of which   6330   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-000617-43
    Sponsor's Protocol Code Number:CLEE011F2301
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2015-05-08
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2015-000617-43
    A.3Full title of the trial
    MONALEESA-3: A randomized double-blind, placebocontrolled study of ribociclib in combination with fulvestrant for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who have received no or only one line of prior endocrine treatment
    Estudio aleatorizado, doble ciego, controlado con placebo de ribociclib en combinación con fulvestrant para el tratamiento de mujeres postmenopáusicas con cáncer de mama avanzado con receptor hormonal positivo, HER2-negativo que no han recibido o que sólo han recibido una línea de tratamiento endocrino previa
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study of Efficacy and Safety of LEE011 with endocrine treatment in Postmenopausal Women with Advanced Breast Cancer
    Estudio que evalúa la eficacia y la seguridad de LEe011 con el tratamiento endocrino en mujeres posmenopáusicas con cáncer de mama avanzado
    A.3.2Name or abbreviated title of the trial where available
    Monaleesa-3
    Monaleesa-3
    A.4.1Sponsor's protocol code numberCLEE011F2301
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorNovartis Farmacéutica, S.A.
    B.1.3.4CountrySpain
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportNovartis Pharma Services AG
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationNovartis Farmacéutica, S.A.
    B.5.2Functional name of contact pointDepartamento Médico Oncología (GMO)
    B.5.3 Address:
    B.5.3.1Street AddressGran Vía de les Corts Catalanes, 764
    B.5.3.2Town/ cityBarcelona
    B.5.3.3Post code08013
    B.5.3.4CountrySpain
    B.5.4Telephone number34900353036
    B.5.5Fax number34932479903
    B.5.6E-maileecc.novartis@novartis.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code LEE011
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNribociclib
    D.3.9.1CAS number 1374639-75-4
    D.3.9.2Current sponsor codeLEE011
    D.3.9.3Other descriptive nameLEE011
    D.3.9.4EV Substance CodeSUB31644
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Faslodex
    D.2.1.1.2Name of the Marketing Authorisation holderAstraZeneca UK Limited
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namefulvestrant
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntramuscular use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNfulvestrant
    D.3.9.1CAS number 129453-61-8
    D.3.9.2Current sponsor codeFULVESTRANT
    D.3.9.3Other descriptive nameFULVESTRANT
    D.3.9.4EV Substance CodeSUB13933MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number250
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule, hard
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    postmenopausal women with HR+, HER2-negative advanced (loco regionally recurrent not amenable to curative therapy or metastatic) breast cancer
    mujeres postmenopáusicas con cáncer de mama avanzado HR+, HER2-negativo que no han recibido o que sólo han recibido un tratamiento endocrino previo para la enfermedad avanzada.
    E.1.1.1Medical condition in easily understood language
    advanced metastatic breast cancer
    cáncer de mama metastásico avanzado
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 18.0
    E.1.2Level LLT
    E.1.2Classification code 10072737
    E.1.2Term Advanced breast cancer
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To determine whether treatment with ribociclib + fulvestrant prolongs progression free survival (PFS) compared to treatment with placebo + fulvestrant in postmenopausal women with HR+, HER2-negative breast cancer.
    El objetivo principal es comparar la supervivencia libre de progresión (SLP) entre ribociclib en combinación con fulvestrant frente a placebo en combinación con fulvestrant en mujeres postmenopáusicas con cáncer de mama avanzado con HR+, HER2-negativo que no recibieron o que sólo recibieron un tratamiento previo endocrino para la enfermedad avanzada.
    E.2.2Secondary objectives of the trial
    1. To determine whether treatment with ribociclib + fulvestrant prolongs overall survival (OS) compared to treatment with placebo + fulvestrant.
    2. To evaluate the two treatment arms with respect to centrally assessed PFS
    3. To evaluate the two treatment arms with respect to overall response rate (ORR), clinical benefit rate (CBR), time to response (TTR) and duration of response (DOR).
    4. To evaluate the two treatment arms with respect to time to deterioration of ECOG performance status.
    5. To evaluate the safety and tolerability of ribociclib in combination with fulvestrant.
    6. To evaluate patient reported outcomes for health-related quality of life in the two treatment arms.
    7. To characterize the pharmacokinetics (PK) of ribociclib (and relevant metabolites) when given in combination with fulvestrant.
    ?Comparar los dos brazos de tratamiento con respecto a la supervivencia global
    ?Evaluar los dos brazos de tratamiento con respecto a la SLP evaluada centralmente
    ?Evaluar los dos brazos de tratamiento con respecto a la tasa de respuesta global, tasa de beneficio clínico, tiempo hasta la respuesta y duración de la respuesta
    ?Evaluar los dos brazos de tratamiento con respecto al tiempo hasta el deterioro del estado funcional del ECOG
    ?Evaluar la tolerabilidad y la seguridad de ribociclib en combinación con fulvestrant,
    ?Evaluar los resultados notificados por la paciente cada 8 ó 12 semanas para la calidad de vida relacionada con la salud (QOL) en los dos brazos de tratamiento
    ?Caracterizar la farmacocinética (PK) de ribociclib (y de los metabolitos relevantes como LEQ803) el día 15 del ciclo 1, del día 1 del ciclo 2 y el día 15 del ciclo 2, cuando se administra en combinación con fulvestrant
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Patient is postmenopausal.
    2. Patient has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer by local laboratory and has HER2-negative breast cancer.
    3. Patient must have either measurable disease by RECIST 1.1 or at least one predominantly lytic bone lesion.
    4. Patient has advanced (loco regionally recurrent not amenable to curative therapy or metastatic) breast cancer.
    Patients may be:
    ? newly diagnosed advanced breast cancer, treatment naïve
    ? relapsed with documented evidence of progression more than 12 months from completion of (neo)adjuvant endocrine therapy with no treatment for metastatic disease
    ? relapsed with documented evidence of progression on or within 12 months from completion of (neo)adjuvant endocrine therapy with no treatment for metastatic disease
    ? relapsed with documented evidence of progression more than 12 months from completion of adjuvant endocrine therapy and then subsequently progressed with documented evidence of progression after one line of endocrine therapy (with either an antiestrogen or an aromatase inhibitor) for metastatic disease
    ? newly diagnosed advanced breast cancer, then relapsed with documented evidence of progression after one line of endocrine therapy (with either an antiestrogen or an aromatase inhibitor)
    5. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
    6. Patient has adequate bone marrow and organ function
    ?Pacientes adultas con ? 18 años en el momento del consentimiento informado y que hayan firmado el consentimiento informado antes de cualquier actividad relacionada con el ensayo y según las pautas locales
    ?La paciente deberá ser postmenopáusica
    ?Pacientes con un diagnóstico confirmado histológicamente y/o citológicamente de cáncer de mama con receptor estrogénico positivo y/o receptor progesterónico positivo
    ?Pacientes con cáncer de mama HER2 negativo
    ?Las pacientes deberán presentar:
    - Enfermedad medible, es decir, por lo menos una lesión medible según los RECIST 1.1
    - En caso de ausencia de enfermedad medible, entonces deberá estar presente por lo menos una lesión ósea predominantemente lítica
    ? Las pacientes pueden presentar:
    - cáncer de mama avanzado de diagnóstico reciente, naïves a tratamiento
    - recaída con evidencia documentada de progresión más de 12 meses desde la finalización de la terapia endocrina (neo)adyuvante sin tratamiento para la enfermedad metastásica
    - recaída con evidencia documentada de progresión en o dentro de los 12 meses desde la finalización de la terapia endocrina (neo)adyuvante sin tratamiento para la enfermedad metastásica
    - recaída con evidencia documentada de progresión más de 12 meses desde la finalización de la terapia endocrina (neo)adyuvante y que hayan progresado posteriormente con evidencia documentada de progresión después de una línea de terapia endocrina (con un antiestrógeno o un inhibidor de la aromatasa) para la enfermedad metastásica
    - cáncer de mama avanzado de diagnóstico reciente, que recayeron posteriormente con evidencia documentada de progresión después de una línea de terapia endocrina (con un antiestrógeno o un inhibidor de la aromatasa)
    ?Pacientes con un estado funcional de 0 ó 1 del Grupo Oncológico Cooperativo del Este (ECOG)
    ?Pacientes con función orgánica y de la médula ósea adecuada
    E.4Principal exclusion criteria
    1. Patient with symptomatic visceral disease or any disease burden that makes the patient ineligible for endocrine therapy per the investigator?s best judgment.
    2. Patient has received prior treatment with chemotherapy (except for neoadjuvant/ adjuvant chemotherapy), fulvestrant or any CDK4/6 inhibitor.
    3. Patient with inflammatory breast cancer at screening .
    4. Patients with Child pugh scroe B or C
    5. Patients has received prior neoadjuvant/adjuvant treatment with antracyclines at cumulative doses of 450mg/m² or more for doxorubicin or 900 mg/m² or more for epirubicin
    6. Patient with CNS involvement unless they are at least 4 weeks from prior therapy completion to starting the study treatment and have stable CNS tumor at the time of screening and not receiving steroids and/or enzyme inducing anti-epileptic medications for brain metastases
    7. Clinically significant, uncontrolled heart disease and/or recent cardiac events including any of the following:
    ? History of angina pectoris, symptomatic pericarditis, or myocardial infarction within 12 months prior to study entry
    ? History of documented congestive heart failure (New York Heart Association functional classification III-IV)
    ? Documented cardiomyopathy
    ? Left Ventricular Ejection Fraction (LVEF) < 50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO)
    ? History of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal arrhythmias, or conduction abnormality in the previous 12 months.
    ? Congenital long QT syndrome or family history of long QT syndrome
    ? Systolic Blood Pressure (SBP) >160 or <90 mmHg
    ? Bradycardia (heart rate < 50 at rest), by ECG or pulse.
    ? On screening, inability to determine the QTcF interval on the ECG (ie: unreadable or not interpretable) or QTcF >450 msec (using Fridericia?s correction). All as determined by screening ECG (mean of triplicate ECGs).
    8. Patient is currently receiving any of the following substances and cannot be discontinued 7 days prior to star the treatment:
    ? Known strong inducers or inhibitors of CYP3A4/5,
    ? That have a known risk to prolong the QT interval or induce Torsades de Pointes.
    ? Those have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5.
    ? Herbal preparations/medications, dietary supplements
    ?Pacientes con enfermedad visceral sintomática
    ?Pacientes que hayan recibido tratamiento previo con quimioterapia (excepto quimioterapia neoadyuvante/adyuvante), fulvestrant o cualquier inhibidor de CDK4/6.
    ?Pacientes con puntuación Child-Pugh B ó C
    ?Pacientes con cáncer de mama inflamatorio en la selección o enfermedad maligna concurrente o enfermedad maligna dentro de los 3 años de la aleatorización.
    ?Enfermedad cardíaca incontrolada y/o eventos cardíacos recientes clínicamente significativos, que incluya algo de lo siguiente:
    - Antecedentes de angina de pecho, pericarditis sintomática o infarto de miocardio dentro de los 12 meses antes de la entrada en el estudio
    - Antecedentes de insuficiencia cardíaca congestiva documentada (clasificación III-IV funcional de la Asociación de Cardiología de Nueva York)
    - Cardiomiopatía documentada
    - Pacientes con fracción de eyección ventricular izquierda (LVEF) < 50%, determinada con ventriculografía isotópica (MUGA) o ecocardiograma (ECO)
    - Antecedentes de cualquier arritmia cardíaca, por ejemplo, arritmias ventriculares, supraventriculares, nodales o anomalías de conducción en los últimos 12 meses
    - Síndrome de QT prolongado congénito o antecedentes familiares de síndrome QT prolongado
    - Presión arterial sistólica (PAS) >160 o <90 mmHg
    - Bradicardia (frecuencia cardíaca < 50 en reposo), con ECG o pulso.
    - En la selección, imposibilidad de determinar el intervalo QTcF en el ECG (es decir: ilegible o no interpretable) o QTcF >450 ms (utilizando la corrección de Fridericia). Todo determinado con el ECG de selección (media de los ECGs triplicados).
    ?Pacientes que no se hayan recuperado de todas las toxicidades relacionadas con las terapias previas antineoplásicas a grado ?1 de la versión 4.03 de los CTCAE-NCI
    ?Pacientes que hayan recibido radioterapia ? 4 semanas o radiación de campo limitado para paliación ? 2 semanas antes de la aleatorización
    ?Pacientes con afectación del sistema nervioso central (SNC), excepto que cumplan TODOS los criterios siguientes:
    ?Por lo menos 4 semanas desde la finalización de la terapia previa (incluyendo radiación y/o cirugía) hasta el inicio del estudio
    - Tumor del SNC clínicamente estable en el momento de la selección y que no reciban esteroides y/o medicaciones antiepilépticas inductoras de enzimas para las metástasis cerebrales
    - Pacientes con cualquier otra condición médica concomitante grave y/o incontrolada que pudiesen, a juicio del investigador, causar riesgos de seguridad inaceptables, contraindicar la participación de la paciente en el estudio clínico o comprometer el cumplimiento con el protocolo.
    ? Pacientes que actualmente estén recibiendo alguna de las siguientes sustancias y que no puedan suspenderlas 7 días antes de iniciar el tratamiento:
    ?Inhibidores o inductores potentes conocidos de CYP3A4/5.
    ? Que posean un riesgo conocido de prolongar el intervalo QT o de inducir Torsades de Pointes.
    ?Que posean un estrecho índice terapéutico y que sean metabolizados predominantemente por CYP3A4/5
    ?Preparaciones/medicaciones herbales, suplementos dietéticos.
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint of the study is PFS, defined as the time from the date of randomization to the date of the first documented progression or death due to any cause. PFS will be assessed according to RECIST 1.1.
    El objetivo primario del estudio es la SSP, que se define como el tiempo desde la fecha de la aleatorización hasta la fecha de la primera progresión documentada o muerte por cualquier causa. PFS se evaluará de acuerdo con RECIST 1.1.
    E.5.1.1Timepoint(s) of evaluation of this end point
    final analysis around 26 months from the date of first patient randomized
    análisis final alrededor de 26 meses desde la fecha de la primera paciente aleatorizada
    E.5.2Secondary end point(s)
    1. Overall survival: Time from date of randomization to the date of death from any cause.
    2. PFS per blinded independent review committee (BIRC) and RECIST 1.1 criteria
    3. ORR: Proportion of patients with best overall response (BOR) of complete response (CR) or partial response (PR) according to RECIST 1.1.
    4. CBR: Percentage of patients with complete response (CR) or partial response (PR) or stable disease (SD) lasting 24 weeks or longer as defined in RECIST 1.1
    5. TTR: Time from randomization to the first documented and confirmed response (complete response or partial response) as defined in RECIST 1.1
    6. DOR: Time from the first documented response (CR or PR) to the first documented progression or death due to underlying cancer as defined in RECIST 1.1
    7. ECOG: Time to definitive deterioration of ECOG performance status from baseline: Time to deterioration of ECOG performance Status.
    8. Safety and tolerability of LEE001: Determined by type, frequency and severity of Adverse Events per CTCAE version 4.03 and type, frequency and severity of laboratory toxicities per CTCAE version 4.03
    9. Time to 10% deterioration in the global health status/QOL scale score of the EORTC QLQ-C30: Patient reported outcomes for health related quality of life
    10. A change from baseline in the global health status/QOL scale score of the EORTC QLQ-C30: Patient reported outcomes for health related quality of life
    11. Summary statistics for PK parameters at steady state, including but not limited to Cmax, Tmax, Ctrough for ribociclib (and relevant metabolites)
    1. supervivencia global: Tiempo desde la fecha de la aleatorización hasta la fecha de muerte por cualquier causa.
    2. PFS por comité de revisión independiente cegado (BIRC) y RECIST 1.1 criterios
    3. TRG: Proporción de pacientes con mejor respuesta global (BOR) de respuesta completa (CR) o respuesta parcial (PR) de acuerdo con RECIST 1.1.
    4. CBR: Porcentaje de pacientes con respuesta completa (CR) o respuesta parcial (RP) o enfermedad estable (SD) que dura 24 semanas o más según se define en RECIST 1.1
    5. TTR: Tiempo desde la aleatorización hasta la primera documentada y respuesta (respuesta completa o respuesta parcial) confirmada como se define en RECIST 1.1
    6. DOR: Tiempo de la primera respuesta documentada (CR o PR) a la primera progresión documentada o muerte debido a cáncer subyacente como se define en los criterios RECIST 1.1
    7. ECOG: Tiempo al deterioro definitivo del estado funcional ECOG de línea de base: la hora de deterioro del estado funcional ECOG.
    8. La seguridad y tolerabilidad de LEE001: Determinado por tipo, frecuencia y gravedad de los eventos adversos por CTCAE versión 4.03 y el tipo, la frecuencia y severidad de las toxicidades de laboratorio por CTCAE versión 4.03
    9. Tiempo a 10% el deterioro en la puntuación de la escala estado de salud / calidad de vida global de la EORTC QLQ-C30: la Paciente informó los resultados de calidad relacionada con la salud de la vida
    10. Un cambio desde el inicio en la puntuación de la escala estado global de salud / calidad de vida de la EORTC QLQ-C30: la Paciente informó de los resultados de calidad relacionada con la salud de la vida
    E.5.2.1Timepoint(s) of evaluation of this end point
    1. 58 months from date of first patient randomized.
    2. PFS per BIRC: up to approximately 26 months
    3. ORR: up to approximately 26 months
    4. CBR: up to approximately 26 months
    5. TTR: up to approximately 26 months
    6. DOR: up to approximately 26 months
    7. ECOG performance status deterioration: up to approximately 26 months
    8. safety and tolerability: up to approximately 26 months
    9. 10% deterioration in QOL: up to approximately 26 months
    10. change from baseline in QOL: up to approximately 26 months
    11. summary statistics for PK parameters: up to approximately 26 month
    1. 58 meses desde la fecha de la primera paciente aleatorizados.
    2. PFS por BIRC: hasta aproximadamente 26 meses
    3. TRG: hasta aproximadamente 26 meses
    4. CBR: hasta aproximadamente 26 meses
    5. TTR: hasta aproximadamente 26 meses
    6. DOR: hasta aproximadamente 26 meses
    7. ECOG performance status deterioro: hasta aproximadamente 26 meses
    8. seguridad y tolerabilidad: hasta aproximadamente 26 meses
    9. 10% el deterioro en la calidad de vida: hasta aproximadamente 26 meses
    10. El cambio de línea de base en la calidad de vida: hasta aproximadamente 26 meses
    11. estadísticos de resumen para los parámetros farmacocinéticos: hasta aproximadamente 26 meses
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Quality of Life (QoL)
    Cuestionarios de calidad de Vida
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned17
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA146
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Australia
    Austria
    Belgium
    Brazil
    Canada
    China
    Colombia
    Czech Republic
    Denmark
    France
    Germany
    Hong Kong
    Hungary
    India
    Israel
    Italy
    Korea, Republic of
    Lebanon
    Malaysia
    Mexico
    Netherlands
    Norway
    Poland
    Portugal
    Russian Federation
    Saudi Arabia
    Singapore
    South Africa
    Spain
    Sweden
    Switzerland
    Taiwan
    Thailand
    Turkey
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the study for a given patient is defined as when the patient permanently
    discontinues study treatment with ribociclib + fulvestrant or placebo + fulvestrant and all the end of trial procedures are completed.
    El final del estudio para un paciente dado se define como cuando el paciente permanentemente discontinúa el tratamiento del estudio con ribociclib + fulvestrant o placebo + fulvestrant y se ha completado el final de los procedimientos del estudio.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months10
    E.8.9.1In the Member State concerned days20
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months10
    E.8.9.2In all countries concerned by the trial days20
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 396
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 264
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male No
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state45
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 289
    F.4.2.2In the whole clinical trial 660
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Patients continuing to derive benefit from study treatment at the end of the study in the opinion of the investigator will be able to continue receiving trial therapy on a separate protocol. Alternatively Novartis will provide study treatment to the investigator as per local regulations.
    Las pacientes que continúan pueden obtener beneficios de tratamiento del estudio al final del estudio, en opinión del investigador podrán seguir recibiendo la terapia del ensayo en un protocolo separado. Alternativamente Novartis proporcionará tratamiento del estudio para el investigador como por las regulaciones locales.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-06-24
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-06-15
    P. End of Trial
    P.End of Trial StatusOngoing
    As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA